Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.49 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089282 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL27742299 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL2089840 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL2088824 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL2087815 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL2088389 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL8899236 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL8898336 | 1.00 | CETP (0.49) | CETPCTRCCNR2SIRT2SIRT1 | |
| SCHEMBL2088395 | 0.97 | CETP (0.46) | CETPCTRCCNR2PTGESALOX5 | |
| SCHEMBL2088889 | 0.97 | CETP (0.46) | CETPCTRCCNR2PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163713-B2 | Trehalose compound and pharmaceutical comprising the compound | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100249057-A1 | TREHALOSE COMPOUND AND PHARMACEUTICAL COMPRISING THE COMPOUND | OTSUKA CHEMICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249057-A1 | TREHALOSE COMPOUND AND PHARMACEUTICAL COMPRISING THE COMPOUND | ADORA3, TREH, ADORA1 | CETP 1341/4885CTRC 1870/4885CNR2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.